Cipla Limited has informed the Exchange regarding 'Update on US Food and Drug Administration (USFDA) inspection on Pharmathen International S.A. '.
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cipla informed exchanges that the USFDA has classified its cGMP inspection at Pharmathen International S.A.'s Rodopi, Greece facility as 'Official Action Indicated' (OAI). Pharmathen is the supply partner for Lanreotide Injection supplied to Cipla USA Inc., Cipla's wholly-owned US subsidiary. This is a follow-up to earlier intimations made on 7th and 14th January 2026 regarding the same inspection. OAI is the most serious USFDA classification, typically indicating significant manufacturing quality concerns that could lead to further regulatory action.
Negative for shareholders — OAI classification on a key supply partner's facility raises concerns about potential supply disruptions or regulatory action on Lanreotide Injection in the US market, which could affect Cipla USA's revenues. Investors should monitor for further developments such as warning letters, import alerts, or remediation timelines.